Compare DGICA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DGICA | VALN |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | France |
| Employees | 851 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.2M | 536.9M |
| IPO Year | N/A | 2021 |
| Metric | DGICA | VALN |
|---|---|---|
| Price | $16.21 | $5.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $19.00 | $15.50 |
| AVG Volume (30 Days) | 80.9K | ★ 81.4K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | $7.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.29 | $5.15 |
| 52 Week High | $21.06 | $12.25 |
| Indicator | DGICA | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 36.01 | 26.83 |
| Support Level | N/A | $5.15 |
| Resistance Level | $17.75 | $6.42 |
| Average True Range (ATR) | 0.39 | 0.24 |
| MACD | -0.11 | 0.09 |
| Stochastic Oscillator | 20.47 | 10.31 |
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.